NewsRoom Articles - Page 1219 of 1465

ThursdayDec 07, 2017 1:00 pm

RadNet, Inc. (NASDAQ: RDNT) Starts Presentation at LD Micro Main Event

RadNet (NASDAQ: RDNT) is a national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 298 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. For more information, visit the company’s website at http://www.radnet.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation…

ThursdayDec 07, 2017 12:30 pm

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) Starts Presentation at LD Micro Main Event

Navidea Biopharmaceuticals (NYSE: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its ManoceptTM platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. For more information, visit…

ThursdayDec 07, 2017 12:30 pm

ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) Starts Presentation at LD Micro Main Event

ImmunoCellular Therapeutics (NYSE: IMUC) is a clinical-stage company developing immune-based therapies for the treatment of brain and other cancers. The company’s lead product candidate, ICT-107, is a patient-specific, dendritic cell-based immunotherapy targeting glioblastoma and is currently being studied in an international Phase 3 trial. ImmunoCellular’s pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer; and the Stem-to-T-cell research program which engineers hematopoietic stem cells to generate cytotoxic T cells. For more information, visit the company's website at imuc.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information…

ThursdayDec 07, 2017 12:30 pm

Arcimoto, Inc. (NASDAQ: FUV) Starts Presentation at LD Micro Main Event

Arcimoto (NASDAQ: FUV) develops and designs electric vehicles currently producing a three-wheeled motorcycle called the SRK. For more information, visit the company’s website at www.arcimoto.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and…

ThursdayDec 07, 2017 12:00 pm

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Starts Presentation at LD Micro Main Event

Onconova Therapeutics (NASDAQ:ONTX) is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes. Onconova's lead candidate, Rigosertib, is a proprietary Phase 3 small molecule agent, which the company believes blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in the clinical stage and several pre-clinical programs. For…

ThursdayDec 07, 2017 12:00 pm

FISION Corp. (FSSN) Starts Presentation at LD Micro Main Event

FISION (OTC: FSSN) is a provider of agile marketing software that simplifies collaboration across global organizations, and more effectively manages brand and marketing content. FISION allows marketing and sales teams to work better together by enabling them to more quickly and easily create, distribute and measure the performance of compelling, localized, on-brand communications. FISION’s patented technology brings capabilities to clients across more than 20 countries, which includes some of the world’s largest corporations in healthcare, hospitality, financial/insurance, software and technology. For more information, visit the company’s website at www.fisiononline.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1)…

ThursdayDec 07, 2017 12:00 pm

OncoSec Medical, Inc. (NASDAQ: ONCS) Starts Presentation at LD Micro Main Event

OncoSec Medical (NASDAQ: ONCS) is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. For more information,…

ThursdayDec 07, 2017 11:30 am

Cesca Therapeutics, Inc. (NASDAQ: KOOL) Starts Presentation at LD Micro Main Event

Cesca Therapeutics (NASDAQ: KOOL) is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets. For more information, visit the company's website at www.cescatherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that…

ThursdayDec 07, 2017 11:30 am

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) Starts Presentation at LD Micro Main Event

Eleven Biotherapeutics (NASDAQ: EBIO) is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the company's targeted protein therapeutics (TPTs) platform. The company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. The company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will…

ThursdayDec 07, 2017 11:30 am

Pressure Biosciences, Inc. (PBIO) Starts Presentation at LD Micro Main Event

Pressure Biosciences (OTC: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Over 250 PCT systems are installed worldwide and over 100 publications cite the advantages of the PCT platform over competitive methods. For more information, visit the company's website at…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

RadNet, Inc. (NASDAQ: RDNT) Starts Presentation at LD Micro Main Event

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) Starts Presentation at LD Micro Main Event

ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) Starts Presentation at LD Micro Main Event

Arcimoto, Inc. (NASDAQ: FUV) Starts Presentation at LD Micro Main Event

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Starts Presentation at LD Micro Main Event

FISION Corp. (FSSN) Starts Presentation at LD Micro Main Event

OncoSec Medical, Inc. (NASDAQ: ONCS) Starts Presentation at LD Micro Main Event

Cesca Therapeutics, Inc. (NASDAQ: KOOL) Starts Presentation at LD Micro Main Event

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) Starts Presentation at LD Micro Main Event

Pressure Biosciences, Inc. (PBIO) Starts Presentation at LD Micro Main Event

NetworkNewsWire Currently Accepts

NetworkNewsWire

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsWire Currently Accepts

Company Search

Site Search